This is the current revision of this page, as edited by JJMC89 bot III (talk | contribs) at 19:42, 20 December 2023 (Moving Category:Hoffmann-La Roche brands to Category:Drugs developed by Hoffmann-La Roche per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands). The present address (URL) is a permanent link to this version.
Revision as of 19:42, 20 December 2023 by JJMC89 bot III (talk | contribs) (Moving Category:Hoffmann-La Roche brands to Category:Drugs developed by Hoffmann-La Roche per Misplaced Pages:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Chemical compound Pharmaceutical compoundClinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H11F3N2O |
Molar mass | 304.272 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Triflunordazepam (also known as Ro5-2904) is a drug which is a benzodiazepine derivative with high GABAA receptor affinity, and has anticonvulsant effects.
See also
References
- DE 1136709
- "Ro5-2904". Archives Internationales de Pharmacodynamie et de Thérapie. 154: 131. 1965.
- So SS, Karplus M (December 1996). "Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors". Journal of Medicinal Chemistry. 39 (26): 5246–56. doi:10.1021/jm960536o. PMID 8978853.
This sedative-related article is a stub. You can help Misplaced Pages by expanding it. |